Ascendis Pharma AS Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Ascendis Pharma AS Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 24 Mar 2022 | Lorem |
| LoA Update: Ascendis Pharma’s achondroplasia asset ACP-015 sees its trial advancement potential grow after positive interim Phase II data reveal | 22 Dec 2021 | Adam Zamecnik |
| Opko, Novo Nordisk and Ascendis’ long-acting growth hormones for paediatric growth hormone deficiency lack pricing premium argument, experts say | 06 Feb 2019 | Mina Moawad,Jennifer C. Smith-Parker |
| Ascendis' Phase III TransCon GH program has fewer than typical 6-12% rate of non-neutralizing antibodies - exec | 11 Jan 2018 | Jennifer C. Smith-Parker |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward